Expert Review of Anticancer Therapy

Papers
(The TQCC of Expert Review of Anticancer Therapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?75
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence66
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review38
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia34
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma27
Current status and novel insights into the role of metastasectomy in the era of immunotherapy24
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review24
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs24
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects24
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy23
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan22
Progress in the development of tissue-based biomarkers for urothelial cancer21
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma21
Progress in histology specific treatments in soft tissue sarcoma21
Current management of familial adenomatous polyposis19
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer17
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis17
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms17
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma17
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium16
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population15
Early detection of hepatocellular carcinoma: roadmap for improvement15
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer14
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?14
NRF2/KEAP1 signaling inhibitors in gynecologic cancers14
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region13
Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19th century13
The trend toward more target therapy in pancreatic ductal adenocarcinoma13
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis13
Current status of robotic surgery for hepato-pancreato-biliary malignancies12
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives12
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis12
Deciding individual treatment for primary retroperitoneal sarcoma12
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer11
Management of breast cancer diagnosed during pregnancy: global perspectives11
Targeting GPRC5D in multiple myeloma11
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy11
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?11
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer11
Anticancer properties of histone deacetylase inhibitors – what is their potential?10
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials10
Advances in systemic therapy for the first-line treatment of unresectable HCC10
Nivolumab plus ipilimumab in malignant pleural mesothelioma10
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and 10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?10
Novel breakthroughs in advanced prostate cancer management10
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond10
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer9
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity9
Emerging treatment options for prostate cancer9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors9
Pembrolizumab in the first-line treatment of advanced head and neck cancer9
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway9
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)9
Benign and malignant cardiac masses: long-term outcomes after surgical resection9
Interventions to reduce the risk of side-effects of cancer treatments in childhood9
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy8
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis8
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy8
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma8
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer8
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?8
Oligometastases in head and neck squamous cell carcinoma patients8
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation8
Molecular-driven treatment for biliary tract cancer: the promising turning point8
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies8
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty8
The association between HALP score and survival in patients treated with immune checkpoint inhibitors7
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature7
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma7
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials7
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers7
How can we better distinguish metastatic tumors from primary tumors in the breast?7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment7
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials7
Cemiplimab for locally advanced and metastatic basal cell carcinoma7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review7
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?7
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic6
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review6
Primary site and treatment impact in unresectable metastatic colorectal cancer6
The optimal management of brain metastases from gestational trophoblastic neoplasia6
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas6
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations6
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia6
Real-world experience with trabectedin for the treatment of recurrent ovarian cancer6
Medullary thyroid carcinoma: a narrative historical review6
Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis6
Venetoclax and beyond: New Horizons in CLL and AML therapy6
Circadian rhythm-based cancer therapy in randomised clinical trials6
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review6
Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer6
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer6
Immune checkpoint inhibition in early-stage triple-negative breast cancer6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms5
Overcoming common emerging barriers to effective neoadjuvant immunotherapies5
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?5
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review5
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma5
Surgical management of intrahepatic cholangiocarcinoma5
How can we refine the prognostic stratification of triple-negative breast cancer?5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis5
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC5
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters5
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis5
Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer5
How can we mitigate treatment-associated morbidity in patients with germ cell tumors?5
Relugolix in the management of prostate cancer5
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape5
Addressing the need for more therapeutic options in neuroendocrine prostate cancer5
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis5
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis5
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors5
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis5
The role of planetary health in urologic oncology5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis5
0.083942890167236